- Market dynamics support growth
- Blue chip client base and repeat business strengths
- Operational gearing means profits are likely to surge
There has been a material increase in pharmaceutical research and development (R&D) activity in infectious diseases during and after the Covid-19 pandemic. However, there are still only 26 infectious diseases that are preventable by available vaccines, according to the World Health Organisation.
Given the costs involved, and the fact that the vast majority of vaccine programmes fail, the drug industry is striving to get smarter in the way it develops vaccines. One way to mitigate risk is to conduct human challenge clinical trials as part of the development process. It’s a buoyant niche business that is driving huge demand for the services of one below the radar small-cap company. For good measure, its shares are materially undervalued.
Download PDF
